$BRTX
BioRestorative Therapies, Inc.

2024 Q3 Form 10-Q Financial Statement

#000149315224031636 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $233.6K $89.10K $64.50K
YoY Change 660.91% 38.14% -9.28%
Cost Of Revenue $18.24K $6.490K
YoY Change
Gross Profit $215.4K $82.61K $64.50K
YoY Change 601.49% 28.08%
Gross Profit Margin 92.19% 92.72% 100.0%
Selling, General & Admin $1.182M $1.259M $2.213M
YoY Change -47.68% -43.1% -38.94%
% of Gross Profit 549.0% 1524.32% 3431.26%
Research & Development $1.320M $1.292M $967.9K
YoY Change 50.89% 33.5% -9.98%
% of Gross Profit 612.95% 1564.2% 1500.61%
Depreciation & Amortization $48.27K $47.71K $41.53K
YoY Change 20.68% 14.88% 31.76%
% of Gross Profit 22.41% 57.75% 64.39%
Operating Expenses $2.502M $2.551M $3.181M
YoY Change -20.18% -19.79% -32.31%
Operating Profit -$2.287M -$2.469M -$3.117M
YoY Change -26.33% -20.78% -32.67%
Interest Expense $1.195M -$1.561M $96.19K
YoY Change 1891.68% -1722.48% -306.37%
% of Operating Profit
Other Income/Expense, Net $1.196M -$1.560M $136.0K
YoY Change 568.1% -1246.89% -391.76%
Pretax Income -$1.091M -$4.029M -$2.981M
YoY Change -62.75% 35.16% -36.25%
Income Tax
% Of Pretax Income
Net Earnings -$1.091M -$4.029M -$2.981M
YoY Change -62.69% 35.16% -36.25%
Net Earnings / Revenue -467.22% -4521.39% -4621.01%
Basic Earnings Per Share -$0.13 -$0.50 -$0.77
Diluted Earnings Per Share -$0.13 -$0.50 -$0.77
COMMON SHARES
Basic Shares Outstanding 6.920M shares 6.770M shares 3.888M shares
Diluted Shares Outstanding 8.121M shares 8.121M shares 3.886M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.09M $14.68M $11.62M
YoY Change 6.93% 26.39% -35.23%
Cash & Equivalents $1.489M $2.252M $1.784M
Short-Term Investments $11.60M $12.43M $9.832M
Other Short-Term Assets $256.1K $295.9K $403.6K
YoY Change -22.4% -26.69% 7.76%
Inventory
Prepaid Expenses
Receivables $165.0K $27.40K $25.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $13.51M $15.00M $12.04M
YoY Change 7.18% 24.58% -34.27%
LONG-TERM ASSETS
Property, Plant & Equipment $378.4K $345.8K $314.1K
YoY Change 23.55% 10.11% 17.74%
Goodwill
YoY Change
Intangibles $646.4K $668.8K $758.6K
YoY Change -12.19% -11.83% 37.74%
Long-Term Investments
YoY Change
Other Assets $22.38K
YoY Change
Total Long-Term Assets $1.065M $1.115M $1.256M
YoY Change -11.08% -11.24% 12.45%
TOTAL ASSETS
Total Short-Term Assets $13.51M $15.00M $12.04M
Total Long-Term Assets $1.065M $1.115M $1.256M
Total Assets $14.57M $16.12M $13.30M
YoY Change 5.6% 21.19% -31.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $401.4K $215.9K $276.0K
YoY Change 76.54% -21.78% -27.02%
Accrued Expenses $682.2K $447.6K $386.3K
YoY Change 24.28% 15.87% 236.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.582M $5.320M $812.9K
YoY Change 391.25% 554.46% 30.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $83.58K
YoY Change -64.29%
Total Long-Term Liabilities $0.00 $0.00 $83.58K
YoY Change -100.0% -100.0% -64.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.582M $5.320M $812.9K
Total Long-Term Liabilities $0.00 $0.00 $83.58K
Total Liabilities $4.582M $5.320M $896.4K
YoY Change 369.89% 493.44% 4.74%
SHAREHOLDERS EQUITY
Retained Earnings -$154.0M -$153.0M -$161.3M
YoY Change -6.2% -5.18% 12.33%
Common Stock $692.00 $692.00 $399.00
YoY Change 47.86% 73.43% 9.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.992M $10.80M $12.40M
YoY Change
Total Liabilities & Shareholders Equity $14.57M $16.12M $13.30M
YoY Change 5.6% 21.19% -31.59%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.091M -$4.029M -$2.981M
YoY Change -62.69% 35.16% -36.25%
Depreciation, Depletion And Amortization $48.27K $47.71K $41.53K
YoY Change 20.68% 14.88% 31.76%
Cash From Operating Activities -$1.700M -$1.865M -$1.130M
YoY Change 44.03% 65.01% -9.66%
INVESTING ACTIVITIES
Capital Expenditures $58.46K $35.30K $29.05K
YoY Change 484.6% 21.51% -121.1%
Acquisitions
YoY Change
Other Investing Activities $995.2K $3.008M $694.9K
YoY Change -10052.2% 332.97%
Cash From Investing Activities $936.8K $2.973M $665.8K
YoY Change -4783.75% 346.56% -583.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -12.84K 411.7K
YoY Change -100.0% -103.12%
NET CHANGE
Cash From Operating Activities -1.700M -1.865M -1.130M
Cash From Investing Activities 936.8K 2.973M 665.8K
Cash From Financing Activities 0.000 -12.84K 411.7K
Net Change In Cash -762.8K 1.095M -52.83K
YoY Change -215.58% -2173.01% -96.2%
FREE CASH FLOW
Cash From Operating Activities -$1.700M -$1.865M -$1.130M
Capital Expenditures $58.46K $35.30K $29.05K
Free Cash Flow -$1.758M -$1.900M -$1.159M
YoY Change 47.73% 63.92% 4.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
15003726 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
11390526 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345807 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
356055 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
78146 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
151447 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
668818 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
713692 usd
CY2024Q2 us-gaap Deferred Costs
DeferredCosts
22381 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
CY2024Q2 BRTX Gain On Exchange Of Warrants
GainOnExchangeOfWarrants
usd
CY2023Q2 BRTX Gain On Exchange Of Warrants
GainOnExchangeOfWarrants
usd
CY2024Q2 BRTX Stock Issued During Period Value Common Stock Issued In Connection With Abeyance Shares
StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
BRTX Gain On Exchange Of Warrants
GainOnExchangeOfWarrants
usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
usd
BRTX Payments For Proceeds From Deferred Offering Costs
PaymentsForProceedsFromDeferredOfferingCosts
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35296 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
89071 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1954831 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3358199 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
411701 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7528027 usd
BRTX Payments For Proceeds From Deferred Offering Costs
PaymentsForProceedsFromDeferredOfferingCosts
22381 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7505646 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
411701 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1367870 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
107069 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
884377 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2252247 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1783646 usd
BRTX Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding
ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
39308 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
8123391 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
595364 usd
us-gaap Net Income Loss
NetIncomeLoss
-6300000 usd
CY2024Q2 BRTX Working Capital
WorkingCapital
9700000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
BRTX Issuance Of Common Stock Held In Abeyance
IssuanceOfCommonStockHeldInAbeyance
usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
usd
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
80700 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
83580 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
162317 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4491969 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1543953 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5319791 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2607345 usd
CY2024Q2 us-gaap Liabilities
Liabilities
5319791 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2607345 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
13982 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
13982 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6919919 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6919919 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4706917 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4706917 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
692 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
471 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
163735564 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
156689256 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152951151 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-146699334 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
10799087 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
10004375 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16118878 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12611720 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64500 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
124100 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
95800 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6490 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6490 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
64500 usd
us-gaap Gross Profit
GrossProfit
117610 usd
us-gaap Gross Profit
GrossProfit
95800 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
902891 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2350313 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2134636 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2278160 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4345356 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6856813 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3181051 usd
us-gaap Operating Expenses
OperatingExpenses
6695669 usd
us-gaap Operating Expenses
OperatingExpenses
8991449 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3116551 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6578059 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8895649 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
96187 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
338542 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
114403 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
911 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39812 usd
BRTX Gain On Exchange Of Warrants
GainOnExchangeOfWarrants
1711698 usd
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1736611 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-2728847 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1559755 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2592848 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4028562 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5709399 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.39
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8121499 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3886309 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3886309 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7400446 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7400446 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3803323 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3803323 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
10004375 usd
CY2024Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
4742243 usd
CY2024Q1 BRTX Stock Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding
StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
-48410 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
985038 usd
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1043336 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2223255 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
14503327 usd
CY2024Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
324322 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4028562 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
10799087 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10290339 usd
CY2023Q1 BRTX Stock Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding
StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
-39308 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1188070 usd
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
2190428 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7172572 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6456957 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6456957 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1164134 usd
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
321534 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
411710 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5709399 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2644936 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2644936 usd
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3351580 shares
CY2024Q1 BRTX Shares Held In Abeyance
SharesHeldInAbeyance
1201580 shares
us-gaap Net Income Loss
NetIncomeLoss
-6251817 usd
us-gaap Net Income Loss
NetIncomeLoss
-12881971 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
90418 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
80877 usd
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
327065 usd
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
206158 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2352696 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4864166 usd
BRTX Noncash Lease Expense
NoncashLeaseExpense
73301 usd
BRTX Noncash Lease Expense
NoncashLeaseExpense
58022 usd
BRTX Gain On Exchange Of Warrants
GainOnExchangeOfWarrants
1711698 usd
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
1873930 usd
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
4217197 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8100 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
39040 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
79778 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
26531 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
105146 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-264064 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
256253 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
80700 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-78737 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-67585 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4182945 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3662831 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10865000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10982932 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
12784535 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7535662 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35296 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
89071 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1954831 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3358199 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
411701 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
107069 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
884377 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1676577 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2252247 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1783646 usd
BRTX Issuance Of Common Stock Held In Abeyance
IssuanceOfCommonStockHeldInAbeyance
15 usd
BRTX Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding
ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
48410 usd
BRTX Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding
ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
39308 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
8123391 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
595364 usd
us-gaap Net Income Loss
NetIncomeLoss
-6300000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4200000 usd
CY2024Q2 BRTX Working Capital
WorkingCapital
9700000 usd
BRTX Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
7500000 usd
BRTX Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
7500000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zmBy2KZzmtD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_863_zvlhiQUZFC5h">Reclassifications</span> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain prior period statements of operations, changes in stockholders’ equity and cash flows amounts have been reclassified to conform to the Company’s fiscal 2024 presentation. These reclassifications have no impact on the Company’s previously reported net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1964341 usd
BRTX Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
7500000 usd
BRTX Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
7500000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zmBy2KZzmtD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_863_zvlhiQUZFC5h">Reclassifications</span> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain prior period statements of operations, changes in stockholders’ equity and cash flows amounts have been reclassified to conform to the Company’s fiscal 2024 presentation. These reclassifications have no impact on the Company’s previously reported net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1964341 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
604226 usd
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
80700 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
604226 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zMZbQ8HywAja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_867_zkERSV7Bm5Z">Customer and Revenue Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the Company’s contract service revenue is derived from one customer. Additionally, all of the Company’s product sales revenue is derived from one customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
80700 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
89100 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64500 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
124100 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
95800 usd
CY2024Q2 BRTX Shares Held In Abeyance
SharesHeldInAbeyance
1201580 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7753947 shares
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
89100 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64500 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
124100 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
95800 usd
CY2024Q2 BRTX Shares Held In Abeyance
SharesHeldInAbeyance
1201580 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8752277 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7753947 shares
CY2024Q2 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
389500 usd
CY2023Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
638000 usd
CY2024Q2 BRTX Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
58122 usd
CY2023Q4 BRTX Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
73686 usd
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
447622 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
711686 usd
CY2024Q2 BRTX Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1466892 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.11
CY2024Q2 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
389500 usd
CY2023Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
638000 usd
CY2024Q2 BRTX Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
58122 usd
CY2023Q4 BRTX Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
73686 usd
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
447622 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
711686 usd
CY2024Q2 BRTX Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1466892 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.11
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.45
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3401608 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.60
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2189947 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
324322 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1485668 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1934716 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.45
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3401608 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.60
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2189947 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
324322 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1485668 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2352696 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M9D
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
324322 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1485668 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2352696 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4864166 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12 pure
us-gaap Operating Lease Cost
OperatingLeaseCost
86530 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
84014 usd
us-gaap Lease Cost
LeaseCost
84014 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2352696 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4864166 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1344375 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M9D
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
324322 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2352696 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4864166 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12 pure
us-gaap Operating Lease Cost
OperatingLeaseCost
86530 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
84014 usd
us-gaap Lease Cost
LeaseCost
86530 usd
us-gaap Lease Cost
LeaseCost
84014 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
86530 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
84014 usd
BRTX Operating Lease Liability Reduction
OperatingLeaseLiabilityReduction
78737 usd
BRTX Operating Lease Liability Reduction
OperatingLeaseLiabilityReduction
67585 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
78146 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
183738 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
83580 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
150480 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
83580 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
86530 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
84014 usd
BRTX Operating Lease Liability Reduction
OperatingLeaseLiabilityReduction
78737 usd
BRTX Operating Lease Liability Reduction
OperatingLeaseLiabilityReduction
67585 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
78146 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
183738 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
83580 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
150480 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
83580 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
86530 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
86530 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
83580 usd
CY2024Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
2189420 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1543953 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2189420 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1115334 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4491969 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
12428218 usd
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
12428218 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
10181618 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
86530 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
86530 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2950 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
83580 usd
CY2024Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
2189420 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1543953 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2189420 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1115334 usd
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
1873930 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4491969 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
12428218 usd
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
12428218 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
10181618 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10181618 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1543953 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10181618 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4491969 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1543953 usd

Files In Submission

Name View Source Status
form10-q_htm.xml Edgar Link completed
0001493152-24-031636-index-headers.html Edgar Link pending
0001493152-24-031636-index.html Edgar Link pending
0001493152-24-031636.txt Edgar Link pending
0001493152-24-031636-xbrl.zip Edgar Link pending
brtx-20240630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
brtx-20240630_def.xml Edgar Link unprocessable
brtx-20240630_lab.xml Edgar Link unprocessable
brtx-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
brtx-20240630_cal.xml Edgar Link unprocessable